Our Clients

Renovo is a biopharmaceutical product company and is the world leader in the development of drugs to reduce scarring.  Scarring can result from acute injury in, or surgery to, the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. These are high value markets of significant unmet medical need.

Juvista^®, Renovo's lead drug for the reduction of scarring in the skin has been safely administered to over 1,500 human subjects and has reported statistical and clinical significance in six Phase 2 efficacy trials.

Renovo announced in June 2007 that it had signed an exclusive licensing agreement with Shire plc to develop and commercialise Juvista. The agreement covers every country in the world except the European Union, the rights to which have been retained by Renovo. 

Under the terms of the deal Renovo has already received an initial payment of US$125 million, consisting of a US$75 million upfront payment and US$50 million equity investment in Renovo Group Plc. Contingent on the successful development and commercialisation of Juvista Renovo will be eligible for further payments of up to $700 million together with escalating royalties on sales

Zesteem^®, Renovo's lead drug for the acceleration of wound healing in the skin, commenced Phase 3 clinical trials in December 2006. Prevascar^TM reported statistically significant Phase 2 efficacy data for the reduction of scarring in the skin in April 2007 and is additionally being investigated for enhancing regeneration of peripheral nerves following injury or trauma.

Buchanan began representing Renovo in August 2006, and has enjoyed raising the profile of the company and the strong management team since then. During this time Buchanan has helped Renovo to:

1. Foster the interest from investors, sell-side analysts and the media.
2. Educate its audiences on its products in development by arranging events that have included technology seminars, pipeline updates, site visits and media interviews.
3. Announce and communicate its exclusive licensing deal with Shire - a deal which was worth up to US$825 million.

In addition, Buchanan has been pleased to offer corporate and strategic advice to Renovo and assist with financial calendar obligations as a listed Company. As a measure of success, Buchanan has helped to raise the analyst following of Renovo from two to six. Renovo also now has an increasingly high media profile. Renovo is valued as at the beginning of 2008 at approximately £250 million.